Second-Line Axi-Cel Prolongs Survival Over Standard ...
Axicabtagene ciloleucel (axi-cel) improved overall and progression-free survival in elderly patients with relapsed/refractory large B-cell lymphoma, as per ZUMA-7 trial subgroup analysis. Axi-cel showed prolonged survival over standard care, suggesting age should not limit CAR T-cell therapy consideration. Adverse effects were noted but axi-cel was deemed a curative second-line option.
Related Clinical Trials
Reference News
Axicabtagene ciloleucel (axi-cel) improved overall and progression-free survival in elderly patients with relapsed/refractory large B-cell lymphoma, as per ZUMA-7 trial subgroup analysis. Axi-cel showed prolonged survival over standard care, suggesting age should not limit CAR T-cell therapy consideration. Adverse effects were noted but axi-cel was deemed a curative second-line option.